On July 9, AstraZeneca fell 6.39% overnight, trading at $177.19 USD/share, with turnover of $387,400 in thin overnight conditions.

The decline followed AstraZeneca's announcement of a deal worth up to $2.1 billion with Sino Biopharmaceutical's unit Chia Tai Tianqing for exclusive rights to develop, manufacture, and commercialize the COPD drug candidate TQC3721 outside China. The agreement includes a $200 million upfront payment and up to $1.9 billion in development, regulatory, and sales milestones. This transaction came just days after a $1.77 billion siRNA collaboration with CSPC Pharmaceutical, raising market concerns over AstraZeneca's pace of capital deployment on early-to-mid-stage assets.

Within the Pharmacy sector, peers remained broadly flat: Eli Lilly up 0.01%, Pfizer up 0.21%, Merck up 0.17%, Johnson & Johnson down 0.08%, and Crinetics Pharmaceuticals unchanged, underscoring AstraZeneca's move as company-specific. The company's next earnings report is scheduled for July 27.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)